Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids

Arthritis and Rheumatology

Volumn 67, Issue 6, 2015, Pages 1629-1636

  Miloslavsky, E M ^a   Specks, U ^b   Merkel, P A ^c   Seo, P ^d   Spiera, R ^e   Langford, C A ^f   Hoffman, G S ^f   Kallenberg, C G M ^g   St Clair, E W ^h   Tchao, N K ⁱ   Ding, L ^j   Ikle D ^k   Villareal, M ^k   Lim, N ^l   Brunetta, P ^m   Fervenza, F C ^b   Monach, P A ⁿ   Stone, J H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e HOSPITAL FOR SPECIAL SURGERY   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ Immune Tolerance Network   (United States)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k RHO INC   (United States)

^l Immune Tolerance Network   (United States)

^m GENENTECH INC   (United States)

ⁿ BOSTON MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; PLACEBO; PREDNISONE; RITUXIMAB; AUTOANTIBODY; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYELOBLASTIN; PEROXIDASE;

ADULT; ANCA ASSOCIATED VASCULITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; MALE; NONSEVERE RELAPSE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RELAPSE; REMISSION; TREATMENT DURATION; WEGENER GRANULOMATOSIS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; GRANULOMATOSIS WITH POLYANGIITIS; IMMUNOLOGY; MAINTENANCE CHEMOTHERAPY; MICROSCOPIC POLYANGIITIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; GRANULOMATOSIS WITH POLYANGIITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAINTENANCE CHEMOTHERAPY; MALE; MICROSCOPIC POLYANGIITIS; MYELOBLASTIN; PEROXIDASE; PREDNISONE; RECURRENCE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84929896074     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39104     Document Type: Article

References (28)

1. Fauci AS, Katz P, Haynes BF, Wolff SM., Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 1979; 301: 235-8.
2. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351-61.
3. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al, for the RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-32.
4. De Groot K, Muhler M, Reinhold-Keller E, Paulsen J, Gross WL., Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol 1998; 25: 492-5.
5. Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, et al, for the European Vasculitis Study Group (EUVAS). Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010; 304: 2381-8.
6. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al, for the European Vasculitis Study Group. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 2461-9.
7. Springer J, Nutter B, Langford CA, Hoffman GS, Villa-Forte A., Granulomatosis with polyangiitis (Wegener's): impact of maintenance therapy duration. Medicine (Baltimore) 2014; 93: 82-90.
8. De Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al, EUVAS (European Vasculitis Study Group). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150: 670-80.
9. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al, for the European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44.
10. Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al, for the French Vasculitis Study Group. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359: 2790-803.
11. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al, for the European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211-20.
12. Carrington CB, Liebow AA., Limited forms of angiitis and granulomatosis of Wegener's type. Am J Med 1966; 41: 497-527.
13. Jayne D., Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol 2001; 13: 48-55.
14. Specks U, Merkel PA, Hoffman GS, Langford CA, Spiera R, Seo P, et al, for the RAVE-ITN Research Group. Design of the Rituximab in ANCA-associated Vasculitis (RAVE) trial. Open Arthritis J 2011; 4: 1-18.
15. Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, et al, for the International Network for the Study of the Systemic Vasculitides (INSSYS). A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum 2001; 44: 912-20.
16. Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, et al, for the RAVE-ITN Research Group. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013; 369: 417-27.
17. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al., Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997; 40: 371-80.
18. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS., The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992; 35: 1322-9.
19. Langford CA, Talar-Williams C, Sneller MC., Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis: long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000; 43: 1836-40.
20. Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, et al, for the Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group. Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 2014; 66: 3151-9.
21. Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, et al, for the French Vasculitis Study Group. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014; 371: 1771-80.
22. McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH., Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol 2012; 7: 240-7.
23. Walsh M, Merkel PA, Mahr A, Jayne D., Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res (Hoboken) 2010; 62: 1166-73.
24. Del Rincon I, Battafarano DF, Restrepo JF, Erikson JM, Escalante A., Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol 2014; 66: 264-72.
25. National Library of Medicine: National Institutes of health. ClinicalTrials.gov study record: The Assessment of Prednisone In Remission Trial (TAPIR): patient centric approach. URL: https://clinicaltrials.gov/ct2/show/NCT01933724.
26. Franssen C, Gans R, Kallenberg C, Hageluken C, Hoorntje S., Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies. J Intern Med 1998; 244: 209-16.
27. Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O., Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012; 71: 955-60.
28. Walsh M, Flossmann O, Berden A, Westman K, Hoglund P, Stegeman C, et al, on behalf of the European Vasculitis Study Group. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64: 542-8.